Theravance Biopharma(Delisted)
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation C+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 16.4x | Better than 54% |
| Forward P/E | 6.8x | Better than 94% |
| Price / Sales | 8.5x | Better than 12% |
| P/E vs own 5-yr range | 85th pctl | Better than 21% |
Growth C+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 27.9% | Better than 89% |
| Net income CAGR (3Y) | -50.5% | Better than 4% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 100.0% | Better than 99% |
| Operating margin | -3.4% | Better than 18% |
| Net margin | 98.5% | Better than 100% |
| Return on equity | 44.8% | Better than 93% |
| Return on invested capital | 35.3% | Better than 97% |
Momentum N/A
Recent price strength, skipping the latest month to avoid short-term noise.
Not enough data to grade this factor.
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 10.9x | Better than 94% |
| Debt to assets | 8.8% | Better than 72% |
| Interest coverage | 53.5x | Better than 90% |
| Free cash flow / net income | 225.2% | Better than 80% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Key statistics
Price & volume
- Prev close
- 0.00
- Open
- 0.00
- Day range
- 0.00 - 0.00
- Avg price
- 0.00
- Volume
- 0
- Turnover
- 0
- Turnover ratei
- 0.00%
- Volume ratioi
- 0.00
- Amplitudei
- 0.00%
- 52-week rangei
- 0.00 - 0.00
Valuation
- P/Ei
- 8.27
- P/E (TTM)i
- 16.38
- P/Bi
- 3.05
- EPSi
- 2.06
- Book value / shi
- 5.58
- Net profit
- 106.95M
- Net assets
- 289.71M
Share structure
- Market cap
- 884.18M
- Float capi
- 440.57M
- Shares out
- 51.92M
- Float sharesi
- 25.87M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2015-10-26
Trading activity
Net capital flow main funds, last 45 sessions
-11.12M net over the window
Short interest
- Shares short
- 1.69M
- % of floati
- 3.25%
- Days to coveri
- 4.50
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Theravance Biopharma(Delisted) (TBPH)?
Theravance Biopharma(Delisted) last traded at 0.00. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Theravance Biopharma(Delisted)'s market cap?
About 884.18M.
What is the P/E ratio of Theravance Biopharma(Delisted)?
The trailing twelve-month P/E is 16.38, above its own 5-year average of 2.05 — toward the top of its historical range (85.17% percentile). See the Valuation tab for the full history.
Does Theravance Biopharma(Delisted) pay a dividend?
Theravance Biopharma(Delisted) does not currently pay a regular dividend.
What is Theravance Biopharma(Delisted)'s StockVane Quant Rating?
The StockVane Momentum strategy currently rates Theravance Biopharma(Delisted) a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-22 19:54:59 · For reference only, not investment advice and not tailored to your situation.
Theravance Biopharma(Delisted) discussion 0 comments